ImmunityBio (IBRX) EBT (2014 - 2026)
ImmunityBio (IBRX) posted quarterly EBT of -$632.8 million for Q1 2026, down 387.13% year-over-year from $220.4 million in Q1 2025, and down 919.1% quarter-over-quarter from -$62.1 million in Q4 2025.
ImmunityBio (IBRX) EBT (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported EBT for 13 consecutive years, with -$632.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 387.13% year-over-year to -$632.8 million; the TTM figure through Mar 2026 stood at -$854.5 million (down 108.71% YoY), while the FY2025 annual figure was -$351.6 million, up 15.0% from the prior year.
- EBT declined to -$632.8 million in Q1 2026 per IBRX's latest filing, from -$62.1 million in the prior quarter.
- Across five years, EBT topped out at -$59.2 million in Q4 2024 and bottomed at -$632.8 million in Q1 2026.
- Historically, EBT has averaged -$141.1 million across 5 years, with a median of -$108.3 million in 2022.
- Annual changes were most pronounced in 2024 — EBT surged 74.65% — and 2026, when it sank 387.13%.
- ImmunityBio's EBT stood at -$108.3 million in 2022, then sank by 115.58% to -$233.5 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then declined by 4.92% to -$62.1 million in 2025, then sank by 919.1% to -$632.8 million in 2026.
- Business Quant data shows IBRX's EBT at -$632.8 million in Q1 2026, -$62.1 million in Q4 2025, and -$67.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -230.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -230.39 Mn |
| Mar 31, 2026 | -632.79 Mn |
| Dec 31, 2025 | -62.09 Mn |
| Sep 30, 2025 | -67.31 Mn |
| Jun 30, 2025 | -92.31 Mn |
| Mar 31, 2025 | -129.90 Mn |
| Dec 31, 2024 | -59.18 Mn |
| Sep 30, 2024 | -85.75 Mn |
| Jun 30, 2024 | -134.58 Mn |
| Mar 31, 2024 | -134.13 Mn |
| Dec 31, 2023 | -233.45 Mn |
| Sep 30, 2023 | -95.64 Mn |
| Jun 30, 2023 | -138.21 Mn |
| Mar 31, 2023 | -116.58 Mn |
| Dec 31, 2022 | -108.29 Mn |
| Sep 30, 2022 | -111.16 Mn |
| Jun 30, 2022 | -94.84 Mn |
| Mar 31, 2022 | -103.00 Mn |
| Dec 31, 2021 | -91.55 Mn |
| Sep 30, 2021 | -88.43 Mn |